RENEW · Hormone and cellular care
Tesamorelin
Hormone science with clinical context.
Tesamorelin acts on growth-hormone-releasing factor pathways. Understanding its specific uses is essential before considering treatment.
Prescription required. Provider evaluation determines eligibility.
Tesamorelin is a growth-hormone-releasing factor analog. Approved Egrifta products are indicated for excess abdominal fat in adults with HIV-associated lipodystrophy.
Tesamorelin stimulates growth hormone release. The approved indication does not make it a general weight-loss or anti-aging treatment.
Preparation, dose and storage depend on the exact formulation. Approved Egrifta formulations have different instructions and are not substitutable.
Your provider reviews the clinical reason for treatment, pituitary history, malignancy history, pregnancy, glucose levels and relevant monitoring.
A specific indication.
Formulation matters.
Tesamorelin is a growth-hormone-releasing factor analog. Approved Egrifta products are indicated for excess abdominal fat in adults with HIV-associated lipodystrophy.
-
A specific indication
Approved use concerns HIV-associated lipodystrophy.
-
Not general weight loss
The approved label excludes weight-loss management.
-
Formulation matters
Different preparations require different instructions.
Care starts with
understanding you.
A treatment decision should take your health history, current medications and goals into account. Your evaluation is the place to discuss questions, potential risks and whether another approach may be more appropriate.
-
Your health in context
Share your medical history, current medications and treatment goals.
-
A considered decision
Discuss the evidence, potential risks and available alternatives.
-
Clear next steps
If treatment is prescribed, follow the instructions for your exact medication and ask how follow-up will work.
Explore your options
with context.
Different treatments have different uses, risks and levels of evidence. Explore this care category, then discuss the options that may fit your clinical needs.
Explore hormone and cellular care-
CJC/Ipamorelin
The precise CJC identity must be specified.
CJC-related peptides and ipamorelin are different substances. The CJC form, including whether it contains a drug affinity complex, must be identified.
Learn more -
Glutathione
Glutathione is present in human cells.
Glutathione is a molecule involved in cellular redox balance. Its natural presence does not mean that taking additional glutathione will produce a particular benefit.
Learn more -
SS-31 Injection
SS-31 refers to elamipretide.
Elamipretide is a peptide that targets mitochondrial cardiolipin. FDA-approved Forzinity has a specific indication for improving muscle strength in patients with Barth syndrome weighing at least 30 kg.
Learn more
A plan begins with
an evaluation.
Completing an assessment does not guarantee a prescription.
-
Share your history
Provide information about your health, medications and goals.
-
Review the options
A licensed provider evaluates whether treatment is clinically appropriate. Further information, testing or another type of care may be needed.
-
Understand your prescription
If prescribed, review the medication, administration directions, risks and follow-up plan before starting.
-
Revisit the plan
Discuss your response and any concerns with your prescriber. Do not change a dose or combine treatments on your own.
Know the important
information.
Every medication has potential risks. Review the complete safety information for the exact product and tell your provider about your medical conditions, allergies, pregnancy or pregnancy plans, and all medicines and supplements you take.
Tesamorelin has important contraindications, including pregnancy, active malignancy and certain pituitary conditions. It can affect IGF-1 and glucose levels and cause fluid retention or hypersensitivity. Review the full information for the exact product.
Compounded medications are not FDA-approved. FDA does not evaluate these preparations for safety, effectiveness or quality before marketing.
Seek emergency care for trouble breathing or swelling of the face, lips or throat. Contact a clinician promptly for severe or concerning symptoms. Do not rely on routine online messaging for an emergency.
Frequently asked questions
FDA-approved tesamorelin is not indicated for weight-loss management.
No. It acts through the growth-hormone-releasing factor pathway.
No. A compounded preparation does not inherit an approved product’s status.
A licensed provider considers your health history, current medications, clinical needs and the evidence for the specific treatment. Further testing or a different type of care may be recommended.
No. A prescription is provided only when the evaluating provider determines that treatment is medically appropriate and available.
Follow your prescriber and pharmacy's instructions for the exact product. Ask before changing a dose, switching formulations or combining treatments.
Your next step starts with your
health.
Share your history and goals so a licensed provider can evaluate which care options may be appropriate for you.
Prescription required. Treatment is not appropriate for everyone. Assessment does not guarantee a prescription.